Serina Therapeutics reported full year 2025 financial results with operating expenses of $24.2 million, net loss attributable to common stockholders of $19.4 million or $(1.91) per share, and cash of $3.1 million as of December 31, 2025. The company highlighted FDA IND clearance for SER-252, Phase 1b trial initiation, and a private placement financing of up to $30 million gross proceeds.
Key takeaways
FDA granted IND clearance for SER-252 in January 2026; first patient dosed in Phase 1b registrational trial in February 2026.
Private placement financing entered March 17, 2026, for initial $15 million gross proceeds, additional $5-15 million, with 50% warrant coverage up to $33.3 million exercise; $16.0 million received as of March 23, 2026.
Greg Bailey, M.D. appointed Co-Chairman of the Board in connection with private placement.
FY2025 net loss attributable to common stockholders $19.4 million or $(1.91) per basic and diluted share on 10,190 thousand shares vs. $11.1 million or $(1.51) per share on 7,359 thousand shares in 2024.
Operating expenses $24.2 million vs. $17.1 million in 2024; R&D $13.2 million vs. $7.5 million; G&A $11.0 million vs. $9.6 million.
Cash and equivalents $3.1 million as of December 31, 2025; ATM sales of 3.0 million shares in 2026 YTD for $10.0 million gross proceeds at average $3.36 per share.